Search Results

REPROCELL USA is proud to announce that it has received funding from MSCRF for both proposals it has submitted for the MSCRF’s January 2024 grant cycle.

REPROCELL Inc. today announced that it has entered into an agreement to grant Gameto Inc., a female-led biotechnology company with a mission to redefine women’s healthcare, a non-exclusive right to use REPROCELL’s StemRNA™ Clinical Seed iPSCs.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD).

This new distributorship will grant REPROCELL customers access to NeuCyte’s pure and ready-to-use iPSC-derived glutamatergic and GABAergic induced neurons (iNs), supplied with astroglia, media and supplements.

Lantern Pharma, a clinical stage oncology biotech leveraging A.I., machine learning (ML) and genomics, announced today that it has selected Reprocell to provide preclinical screening and drug sensitivity work for its portfolio of oncology drugs

• REPROCELL will provide custom drug discovery assays using live human tissues to improve the prediction of drug safety and efficacy • The collaboration is part of Medicines Discovery Catapult’s Virtual R&D network, which aims to support UK SMEs develop and execute their drug discovery projects with industrial rigour

Science Exchange announced today that ReproCELL has selected the Science Exchange platform as the primary marketplace to offer access to its predictive drug discovery assays for the biopharma research community.

The Maryland Stem Cell Research Commission is pleased to announce the next round of awards granting a total of more than $15.4 million.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed an agreement with REPROCELL Ltd., a contract research organization (CRO), providing a unique combination of products and services to power translational research, to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohn’s disease patients.

Q Therapeutics has patented a process to manufacture glial-restricted progenitor (GRP) cells from any tissue source.